Redhill Biopharma Ltd (RDHL) — Cash Flow-to-Debt Ratio
Redhill Biopharma Ltd (RDHL) has a Cash Flow-to-Debt Ratio of -0.11x as of June 2025, meaning its operating cash flow of $-2.51 Million could theoretically repay 0% of its total liabilities ($22.79 Million) in one year. See RDHL free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Redhill Biopharma Ltd Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Redhill Biopharma Ltd across 15 annual periods. Also explore RDHL net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Redhill Biopharma Ltd (2010–2024)
Year-by-year debt coverage analysis for Redhill Biopharma Ltd. For market capitalisation and broader financial context, see RDHL market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.41x | $-9.37 Million | $22.73 Million | ▲ +75.9% |
| 2023 | -1.71x | $-35.82 Million | $20.98 Million | ▼ -1112.7% |
| 2022 | -0.14x | $-29.18 Million | $207.27 Million | ▲ +62.7% |
| 2021 | -0.38x | $-65.05 Million | $172.31 Million | ▼ -29.3% |
| 2020 | -0.29x | $-48.58 Million | $166.38 Million | ▲ +89.9% |
| 2019 | -2.89x | $-40.75 Million | $14.10 Million | ▲ +5.8% |
| 2018 | -3.07x | $-34.46 Million | $11.22 Million | ▲ +15.8% |
| 2017 | -3.65x | $-44.77 Million | $12.28 Million | ▼ -48.5% |
| 2016 | -2.45x | $-28.26 Million | $11.51 Million | ▲ +7.0% |
| 2015 | -2.64x | $-17.83 Million | $6.75 Million | ▲ +17.0% |
| 2014 | -3.18x | $-12.23 Million | $3.85 Million | ▲ +9.0% |
| 2013 | -3.49x | $-8.44 Million | $2.42 Million | ▲ +44.6% |
| 2012 | -6.30x | $-6.79 Million | $1.08 Million | ▼ -88.0% |
| 2011 | -3.35x | $-4.69 Million | $1.40 Million | ▼ -2386.9% |
| 2010 | -0.13x | $-1.63 Million | $12.10 Million | — |